Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity

Kidney-type Glutaminase [KGA/isoenzyme Glutaminase C (GAC)] is becoming an important tumor metabolism target in Cancer chemotherapy. Its allosteric inhibitor, CB839, showed early promise in Cancer therapeutics but limited efficacy in in vivo Cancer models. To improve the in vivo activity, we explored a bioisostere replacement of the sulfur atom in bis-2-(5-phenylacetamido-1,2,4-thiadiazol)ethyl sulfide and CB839 analogues with selenium using a novel synthesis of the selenadiazole moiety from carboxylic acids or nitriles. The resulting selenadiazole compounds showed enhanced KGA inhibition, more potent induction of Reactive Oxygen Species, improved inhibition of Cancer cells, and higher cellular and tumor accumulation than the corresponding sulfur-containing molecules. However, both CB839 and its selenium analogues show incomplete inhibition of the tested Cancer cells, and a partial reduction in tumor size was observed in both the glutamine-dependent HCT116 and aggressive H22 liver Cancer xenograft models. Despite this, tumor tissue damage and prolonged survival were observed in Animals treated with the selenium analogue of CB839.